Mission Pharmacal Company Launches Ferralet(R) 90 for Treatment of the Leading Cause of Anemia in the U.S.
SAN ANTONIO, May 20 /PRNewswire/ -- Mission Pharmacal announced the launch of Ferralet(R) 90, a new prescription oral iron supplement for treatment of iron deficiency anemia (IDA) that is responsive to oral iron therapy. IDA is a depletion of stored iron that prevents maturation of red blood cells. Ferralet 90 contains 90 mg of carbonyl iron as well as essential vitamins and minerals to help patients replenish iron stores in an effective, safe and tolerable manner. Iron deficiency is the most common nutritional deficiency and the leading cause of anemia in the United States.(1)
"If left untreated, IDA has the potential to interfere with the body's vital functions, such as the nervous system, cardiovascular and immune system function. Women of child bearing age are at highest risk of developing iron deficiency anemia, and screening for IDA should be part of every woman's annual medical check up exam," said Miriam Nelson, Ph.D., a leading health and nutrition expert and author of the best-selling Strong Women book series. "The good news is that new IDA supplements, such as Ferralet 90, that are effective and tolerable can help restore iron levels back into normal range."
One in five women is iron deficient and at risk for developing anemia.(2) Menstruation is a leading cause of iron deficiency anemia in women by the Centers for Disease Control and Prevention.(3)
Women with IDA may better tolerate Ferralet 90 over other traditional iron supplements. Ferralet 90 contains carbonyl iron, which works with the body to regulate absorption at a rate determined by gastric acid production. This prolonged solubilization and absorption is the key to carbonyl iron's safety and tolerability.(4) Ferralet 90 is free of lactose and gluten, features a vanilla scent and contains docusate sodium, a gentle and effective stool softener, to help prevent side effects that may occur in women who are sensitive to iron therapy.
Ferralet 90 also contains vitamin C to further aid in iron absorption, folic acid to bolster red blood cell development and vitamin B12 to support red blood cell generation.
"Mission Pharmacal recognizes the unique health and nutritional needs of women and is proud to offer healthcare providers an improved option to help meet the specific needs of iron deficiency anemia patients in the United States," said Neil Walsdorf, Jr., president of Mission Pharmacal. "Ferralet 90 builds on the benefits of existing iron supplements, but offers additional vitamins and minerals to help improve the overall health of women and aid in compliance."
About the Ferralet(R) 90
Ferralet(R) 90 is marketed by Mission Pharmacal Company based in San Antonio, Texas. Ferralet 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence and dietary needs. Ferralet 90 is available by prescription.
Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six. Ferralet 90 should be kept out of the reach of children. In case of accidental overdose of Ferralet 90, call a doctor or poison control center immediately. Please see full Prescribing Information, including boxed WARNING, for Ferralet 90 at www.ferralet90.com.
About Mission Pharmacal
Mission Pharmacal is a privately-held pharmaceutical company based in San Antonio, Texas. For more than 60 years, the company has been dedicated to identifying unmet health needs in the marketplace and developing innovative prescription and over-the-counter products to meet them. Currently, Mission Pharmacal provides physicians and consumers with pharmaceutical and nutritional products. For more information, visit www.missionpharmacal.com.
3 Centers for Disease Control and Prevention. Nutrition for Everyone.
Iron Deficiency Anemia. http://www.cdc.gov/nccdphp/dnpa/nutrition/nutrition_for_everyone/iron_deficien cy/ (To view this link, please copy and paste it into your Internet browser)
4 Brittenham GM, Klein HG et al. Preserving the national blood supply.
Hematology Am Soc Hematol Educ Program. 2001: 422-432.
CONTACT: Ami Shah of GCI Group, +1-212-537-8048, ashah@gcigroup.com
Web site: http://www.missionpharmacal.com/
http://www.ferralet90.com/